Trials / Completed
CompletedNCT02396862
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 272 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) | Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds |
Timeline
- Start date
- 2015-12-09
- Primary completion
- 2018-01-17
- Completion
- 2018-03-26
- First posted
- 2015-03-24
- Last updated
- 2019-03-27
Locations
10 sites across 4 countries: United States, Japan, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02396862. Inclusion in this directory is not an endorsement.